We wouldn't blame UroGen Pharma Ltd. (NASDAQ:URGN) shareholders if they were a little worried about the fact that Mark Schoenberg, the Chief Medical Officer recently netted about US$2.9m selling shares at an average price of US$47.05. Probably the most concerning element of the whole transaction is that the disposal amounted to 51% of their entire holding.

UroGen Pharma Insider Transactions Over The Last Year

Notably, that recent sale by Mark Schoenberg is the biggest insider sale of UroGen Pharma shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$45.94. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

Mark Schoenberg sold a total of 68.05k shares over the year at an average price of US$44.09. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

Insider Ownership Of UroGen Pharma

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Insiders own 1.9% of UroGen Pharma shares, worth about US$43m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At UroGen Pharma Tell Us?

An insider sold stock recently, but they haven't been buying. And even if we look at the last year, we didn't see any purchases. While insiders do own shares, they don't own a heap, and they have been selling. So we'd only buy after careful consideration. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing UroGen Pharma. For example, UroGen Pharma has 3 warning signs (and 1 which shouldn't be ignored) we think you should know about.

Of course UroGen Pharma may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.